About
SEC Filings
Back


Form S-1/A
FIBROCELL SCIENCE, INC. filed this Form S-1/A on 12/04/2017
Document Outline
Entire Document (634.5 KB)
Subdocument 1 - S-1/A - S-1/A
Page 1 - As filed with the Securities and Exchange Commission on December 4, 2017
Page 2 - The information contained in this preliminary prospectus is not complete and may be changed. We may
Page 3 - TABLE OF CONTENTS
Page 4 - PROSPECTUS SUMMARY
Page 5 - Intrexon Collaborations
Page 6 - Phase 1/2 Clinical Trial of FCX-007 for RDEB
Page 7 - FCX-013 for Moderate to Severe Localized Scleroderma
Page 8 - New Gene Therapy Program for Arthritis and Related Conditions
Page 9 - Corporate Information
Page 10 - THE OFFERING
Page 11 - N/A
Page 12 - Outstanding Shares
Page 13 - RISK FACTORS
Page 14 - Management will have broad discretion as to the use of the proceeds from this offering, and we may n
Page 15 - There is no public market for the common warrants or the pre-funded warrants in this offering.
Page 16 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 17 - N/A
Page 18 - SELECTED FINANCIAL DATA
Page 19 - Fibrocell Science, Inc.
Page 20 - Fibrocell Science, Inc.
Page 21 - USE OF PROCEEDS
Page 22 - N/A
Page 23 - MARKET PRICE OF OUR COMMON STOCK
Page 24 - CAPITALIZATION
Page 25 - N/A
Page 26 - DILUTION
Page 27 - N/A
Page 28 - DESCRIPTION OF CAPITAL STOCK
Page 29 - Voluntary Conversions by Holders.
Page 30 - Liquidation Preference.
Page 31 - No Exchange Listing of Preferred Shares.
Page 32 - Preferred Stock
Page 33 - Transfer Agent and Registrar
Page 34 - DESCRIPTION OF SECURITIES WE ARE OFFERING
Page 35 - Cashless Exercise
Page 36 - Pre-Funded Warrants
Page 37 - Fundamental Transactions
Page 38 - CERTAIN RELATIONSHIPS AND TRANSACTIONS WITH RELATED PERSONS
Page 39 - Registration Rights Agreement
Page 40 - PRINCIPAL STOCKHOLDERS
Page 41 - N/A
Page 42 - N/A
Page 43 - UNDERWRITING
Page 44 - Underwriter Warrants
Page 45 - Nasdaq Capital Market Listing
Page 46 - Indemnification
Page 47 - LEGAL MATTERS
Page 48 - WHERE YOU CAN FIND MORE INFORMATION
Page 49 - Up to 9,500,000 Units
Page 50 - PART II
Page 51 - Item 15. Recent Sales of Unregistered Securities.
Page 52 - Conversion of 2016 Convertible Notes
Page 53 - N/A
Page 54 - N/A
Page 55 - EXHIBIT INDEX
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - SIGNATURES
Subdocument 2 - EX-5.1 - EX-5.1
Page 1 - EXHIBIT 5.1
Page 2 - N/A
Page 3 - This opinion letter has been prepared for use in connection with the Registration Statement. We assu
Subdocument 3 - EX-23.1 - EX-23.1
Page 1 - EXHIBIT 23.1



Printer Friendly Version E-mail this page RSS E-mail Alerts Download Financial Tear Sheet